

Electronically filed on 3 August 2010

Customer No.: 20462

Attorney Docket No.: PU60404

Confirmation No.: 9920

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Mc Allister et al.	4 August 2010
Serial No.:	10/565,462	Group Art Unit No.: 1615
Filed:	20 January 2006	Examiner: S. Tran
For:	PHARMACEUTICAL FORMULATION	

Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

Supplemental Information Disclosure Statement Under 37 C.F.R. §1.97©

Sir:

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This information disclosure statement is being filed under the provisions of 37 C.F.R. §1.97(c)(2), i.e., **after** three months of the filing date of the subject application or after the mailing date of the first Office Action on the merits, whichever event occurred last but **before** the mailing date of a either a Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Applicants also submit for the Examiners consideration a listing of their copending and related applications. These are shown on page 3 of the attached 1449 form.

Serial No.: 10/565,462
Group Art Unit No.: 1615

Applicants also submit for the record copies of the most recent office actions from pending applications: USSN 10/060849; USSN 10/470,438; USSN 10/470,439; USSN 10/060,603; USSN 10/895,588; USSN 10/598,810; and USSN 11/078077.

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,

Klara G. Winter

Dara L Dinner
Attorney for Applicants
Registration No. 33,680

GLAXOSMITHKLINE
Global Patents - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7481
Facsimile (610) 270-5090